N-glycolylneuraminic acid-containing ganglioside (NeuGcGM3) (NeuGcGM3)

N-glycolylneuraminic acid-containing ganglioside (NeuGcGM3) is a tumor-associated carbohydrate antigen (TACA) that is highly expressed in various human malignancies but is virtually absent in normal human tissues. This differential expression is a result of a functional deletion in the human CMAH gene, which prevents the endogenous synthesis of N-glycolylneuraminic acid (NeuGc) from N-acetylneuraminic acid (NeuAc). However, tumor cells can acquire NeuGc from dietary sources or through metabolic bypasses, incorporating it into gangliosides like GM3 to facilitate immune evasion and tumor progression. The P3 monoclonal antibody is a murine IgM that specifically recognizes NeuGc-containing gangliosides and sulfatides, and its idiotype (antigen-binding domain) has been used as a template to develop anti-idiotype vaccines like Racotumomab. By mimicking the NeuGcGM3 epitope, these vaccines stimulate the patient's immune system to produce a specific response against tumor cells expressing the ganglioside, making it a promising target for immunotherapy in lung, breast, and pediatric cancers.

Other names

N-glycolyl-GM3NeuGc-GM3Hanganutziu-Deicher antigenP3 monoclonal antibody antigenNGcGM3

Anti-idiotype vaccine (Racotumomab) mimics the NeuGcGM3 epitope to induce an active immune response; Direct monoclonal antibody binding to induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).